EpiHeart

EpiHeart is a Finnish medical technology company focusing on heart regeneration through localized therapeutic delivery. The company has developed the EpiCure device, a proprietary epicardial delivery system that allows surgeons to deliver cell therapies or biological agents directly to the myocardium during cardiac surgery. This approach aims to address the challenges of poor cell retention and systemic side effects associated with traditional delivery methods. Currently in the clinical stage, EpiHeart's solution is primarily targeted at patients undergoing coronary artery bypass grafting (CABG) who suffer from heart failure. By combining advanced medical devices with regenerative medicine, EpiHeart seeks to restore cardiac function and improve long-term patient outcomes.